MYTX-011, a cMET-Targeting Antibody-Drug Conjugate (ADC), In Patients with Advanced NSCLC: Dose Escalation Results In The Phase 1 Kismet-01 Study
Time: 8:00 am
day: Scientific Program Day One AM
Details:
- Examining the safety and tolerability of MYTX-011 in patients with advanced NSCLC
- Evaluating the PK of MYTX-011 in patients with advanced NSCLC
- Analyzing the preliminary efficacy of MYTX-011 in patients with advanced NSCLC
